RT Journal Article
SR Electronic
T1 D-dimer dynamics in hospitalized COVID-19 patients: potential utility for diagnosis of pulmonary embolism
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.21.20193953
DO 10.1101/2020.09.21.20193953
A1 Cerdà, Pau
A1 Ribas, Jesus
A1 Iriarte, Adriana
A1 Mora-Luján, José María
A1 Torres, Raquel
A1 Río, Belén del
A1 Jofre, Héctor Ignacio
A1 Ruiz, Yolanda
A1 Huguet, Marta
A1 Fuset, Maria Paz
A1 Martínez-Yélamos, Sergio
A1 Santos, Salud
A1 Llecha, Núria
A1 Corbella, Xavier
A1 Riera-Mestre, Antoni
YR 2020
UL http://medrxiv.org/content/early/2020/09/23/2020.09.21.20193953.abstract
AB Background A higher incidence of thrombotic events, mainly pulmonary embolism (PE), has been reported in hospitalized patients with COVID-19. The main objective was to assess clinical and weekly laboratory differences in hospitalized COVID-19 patients according to occurrence of PE.Methods This retrospective study included all consecutive patients hospitalized with COVID-19 who underwent a computed tomography (CT) angiography for PE clinical suspicion. Clinical data and median blood test results distributed into weekly periods from COVID-19 symptoms onset were compared between PE and non-PE patients.Results Ninety-two patients were included, 29 (32%) had PE. PE patients were younger (63.9 (SD13.7) vs 69.9 (SD12.5) years). Clinical symptoms and COVID-19 CT features were similar in both groups. PE was diagnosed after a mean of 20.0 (SD8.6) days from the onset of COVID-19 symptoms. Corticosteroid boluses were more frequently used in PE patients (62% vs. 43%). Median values [IQR] of D-dimer in PE vs non-PE patients were: week 2 (2010.7 [770.1-11208.9] vs 626.0 [374.0-2382.2]; p=0.04); 3 (3893.1 [1388.2-6694.0] vs 1184.4 [461.8-2447.8]; p=0.03); and 4 (2736.3 [1202.1-8514.1] vs 1129.1 [542.5-2834.6]; p=0.01). Median fold-increase of D-dimer between week 1 and 2 differed between groups (6.64 [3.02-23.05] vs 1.57 [0.64-2.71], p=0.003); ROC curve AUC was 0.879 (p=0.003) with a sensitivity and specificity for PE of 86% and 80%, respectively.Conclusions Among hospitalized COVID-19 patients, D-dimer levels are higher at weeks 2, 3 and 4 after COVID-19 symptom onset in patients who develop PE. This difference is more pronounced when the fold increase between weeks 1 and 2 is compared.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was provided for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by the Ethics Committee of the Hospital Universitari de Bellvitge (Barcelona, Spain; approval number PR178/20).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed for the current study are available from the corresponding author on reasonable request.